about
Genome-wide association study identifies ephrin type A receptors implicated in paclitaxel induced peripheral sensory neuropathyRegulatory polymorphisms in β-tubulin IIa are associated with paclitaxel-induced peripheral neuropathy.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitroAssessment of whole genome amplification for sequence capture and massively parallel sequencing.Histone H1 interphase phosphorylation becomes largely established in G1 or early S phase and differs in G1 between T-lymphoblastoid cells and normal T cells.Single-nucleotide polymorphisms of ABCG2 increase the efficacy of tyrosine kinase inhibitors in the K562 chronic myeloid leukemia cell line.Semi-physiologically based pharmacokinetic modeling of paclitaxel metabolism and in silico-based study of the dynamic sensitivities in pathway kinetics.The pan-ErbB tyrosine kinase inhibitor canertinib induces caspase-mediated cell death in human T-cell leukemia (Jurkat) cells.Association of ABCB1 polymorphisms with survival and in vitro cytotoxicty in de novo acute myeloid leukemia with normal karyotype.Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Spontaneous reversal of p-glycoprotein expression in multidrug resistant cell lines.Melanin inhibits cytotoxic effects of doxorubicin and daunorubicin in MOLT 4 cells.CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity.GWAS-based association between RWDD3 and TECTA variants and paclitaxel induced neuropathy could not be confirmed in Scandinavian ovarian cancer patients.Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.ABCB1 gene polymorphisms are associated with suicide in forensic autopsies.Identification of candidate SNPs for drug induced toxicity from differentially expressed genes in associated tissues.Pharmacogenomics of importance for paclitaxel chemotherapy.Comparison of two types of population pharmacokinetic model structures of paclitaxel.Effects of nicotine, its metabolites and tobacco extracts on human platelet function in vitro.Validation of whole genome amplification for analysis of the p53 tumor suppressor gene in limited amounts of tumor samples.Pharmacogenetics, plasma concentrations, clinical signs and EEG during propofol treatment.Decreased survival in normal karyotype AML with single-nucleotide polymorphisms in genes encoding the AraC metabolizing enzymes cytidine deaminase and 5'-nucleotidase.Pegylated liposomal doxorubicin as first-line monotherapy in elderly women with locally advanced or metastatic breast cancer: novel treatment predictive factors identified.The pharmacogenetics of metformin and its impact on plasma metformin steady-state levels and glycosylated hemoglobin A1c.The pan-ErbB receptor tyrosine kinase inhibitor canertinib promotes apoptosis of malignant melanoma in vitro and displays anti-tumor activity in vivo.Irreversible pan-ERBB inhibitor canertinib elicits anti-leukaemic effects and induces the regression of FLT3-ITD transformed cells in mice.Impact of CYP3A5*3 and CYP2C8-HapC on paclitaxel/carboplatin-induced myelosuppression in patients with ovarian cancer.Microtubule-targeting drugs and personalization of cancer treatment.Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.ABCB1 G1199A polymorphism and ovarian cancer response to paclitaxel.Measurement of paclitaxel and its metabolites in human plasma using liquid chromatography/ion trap mass spectrometry with a sonic spray ionization interface.beta-Tubulin mutations in ovarian cancer using single strand conformation analysis-risk of false positive results from paraffin embedded tissues.Correlations between metabolism and structural elements of the alicyclic fentanyl analogs cyclopropyl fentanyl, cyclobutyl fentanyl, cyclopentyl fentanyl, cyclohexyl fentanyl and 2,2,3,3-tetramethylcyclopropyl fentanyl studied by human hepatocytes anABCB1 Variation Affects Myelosuppression, Progression-free Survival and Overall Survival in Paclitaxel/Carboplatin-treated Ovarian Cancer PatientsThe influence of ABCG2 polymorphism on erlotinib efflux in the K562 cell lineBiotransformation of the New Synthetic Cannabinoid with an Alkene, MDMB-4en-PINACA, by Human Hepatocytes, Human Liver Microsomes, and Human Urine and BloodWhole-genome sequencing of human remains to enable genealogy DNA database searches - A case report
P50
Q28943314-E53FE687-4C7D-486D-8108-470AB167BAE8Q36877796-3A735269-449A-4638-A7FF-05AE1D540B23Q37140624-43FB4C24-5987-4FAC-BA33-BB58A42ED7F7Q37444902-DFBF3E2D-BA88-4394-91D8-B56F72983504Q38540494-9DF2ADF6-10B8-4D4D-8AA3-F7BCE33D3A1CQ39045073-984D8E16-4D0B-4413-AD31-61CBF1448B6FQ39292079-50A218FB-DC07-417E-A457-C75FFACF0A54Q39525469-5FCE8563-438F-4E85-BEF9-CFFAB265D86BQ39645483-C3978C0C-D1D7-44FD-B6B7-7AFE3C3B6290Q39702921-DEF66FA3-7382-4718-B545-BBF55A5E7D55Q40607500-25A0568F-7594-442D-83AE-48184BD14B72Q41915596-EBE2CB0E-2686-4A15-967E-DCD135D2DF17Q43200942-F9B0335E-0F60-4C90-B266-8EB231C26DF8Q43474093-125D0A9E-3F33-466A-B3E5-99C2BF4136CEQ46163330-159DB80A-9ADB-406D-881F-A77485E71544Q46242458-6D77574A-A563-46F4-9173-A743E2743783Q46364704-189AD5DB-55A6-4A91-9F81-4D5D610A1925Q46563276-897C5F4C-CA45-421C-A2C2-AAA82882DA46Q46847743-6D7F26AF-F601-4BB7-A4C3-995815B2787CQ46861096-E5654A52-6088-4578-860D-7A19F5453259Q47329450-D246050D-FECE-4868-AD22-519E2D622541Q47862497-EA6868AE-9FB4-4B6F-96AE-DE2FFE013D57Q47965783-5AE5B883-34F8-46CB-B83B-903750A333ABQ50508373-08CD49A5-817E-4DED-81CE-4FA8843026F7Q50510276-C3C01916-F6D4-432D-BF12-5D94EE18B132Q50510432-1D65ACBD-FBE4-444D-B226-7FD48CE3C1E1Q50510432-20B2D020-FAFC-407C-9BE2-AED2427FA6D7Q50514234-1B0AD31F-DC0E-43BD-8225-6630D3D1C1A3Q50518000-4899D044-85CC-409A-A408-7BD1A7C0DCEEQ50522019-B287A6AE-E1A8-4B21-94D3-E8D3DB1F8218Q50526560-C8E357DC-256B-4B06-9E35-C71A65C272AFQ50535778-F58CEBC7-742B-4B01-B6E3-1ED3164DE86EQ50557593-47E0AB2D-9F38-4FA6-A369-B20E86F566D8Q50666167-5335BDC1-9FB9-4555-B60B-2F7F31834B0BQ50725952-382DB481-9181-4C96-A2C5-06CB56C7E14CQ50762508-F1AEA23D-B097-460C-B332-579A482F9EA4Q58552585-C4B1B207-CF6F-44C3-ACB8-F1BB07950EC3Q58888958-8CF61C1E-A077-44AE-84AB-5BC5FACFA03FQ91717990-EF1AD7E3-CF60-41D3-9C95-F937F6E412B1Q92063040-2523B72C-7CD9-4E6D-9DA3-1228B9890243
P50
description
hulumtues
@sq
researcher
@en
ricercatore
@it
wetenschapper
@nl
հետազոտող
@hy
name
Henrik Gréen
@ast
Henrik Gréen
@en
Henrik Gréen
@es
Henrik Gréen
@nl
Henrik Gréen
@sl
type
label
Henrik Gréen
@ast
Henrik Gréen
@en
Henrik Gréen
@es
Henrik Gréen
@nl
Henrik Gréen
@sl
prefLabel
Henrik Gréen
@ast
Henrik Gréen
@en
Henrik Gréen
@es
Henrik Gréen
@nl
Henrik Gréen
@sl
P214
P906
P106
P1153
7202758564
P21
P213
0000 0000 5132 8007
P214
P31
P496
0000-0002-8015-5728
P569
1975-01-01T00:00:00Z
P735
P7859
viaf-36901509